Skip to content

US · ICLR · MEDICAL - DIAGNOSTICS & RESEARCH

ICON Public Limited Company (ICLR) intrinsic value and stock valuation

$186.71as of 2026-11-21 · Mkt cap 12.6B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ICON Public Limited Company DCF and intrinsic value

InvestorsCraft values ICLR with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ICLR’s statements →

ICON Public Limited Company Graham Number

Graham Number: $87.83d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Dublin, DU D18 X5R3 iconplc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$8.25B+24.2% 5y CAGRd
20112025
Net income
$229.3M-6.9% 5y CAGRd
20112025
Free cash flow
$862M+9.7% 5y CAGRd
20112025
Total equity
$9.19B+37.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$8.25B$8.28B$8.12B$7.74B$5.48B
Operating income$1.01B$1.1B$956.2M$795.2M$378.5M
Net income$229.3M$791.5M$612.3M$505.3M$153.2M
EPSd$2.9M$9.53M$7.4M$6.13M$2.25M
Operating cash flow$1.04B$1.29B$1.16B$563.3M$829.1M
Capital expenditure-$-174.21M-$-168.06M-$-140.69M-$-142.16M-$-93.75M
Free cash flow$862M$1.12B$1.02B$421.2M$735.4M
Total assets$16.3B$16.9B$17B$17.2B$17.4B
Total debt$3.56B$3.6B$3.94B$4.83B$5.65B
Net debt$2.91B$3.06B$3.56B$4.54B$4.89B
Total equity$9.19B$9.52B$9.24B$8.5B$8.07B
Cash and short-term investments$647.3M$538.8M$380.1M$290.5M$753.9M
Income statement
20252024202320222021
Revenue$8.25B$8.28B$8.12B$7.74B$5.48B
Cost of revenue$6.08B$5.85B$5.72B$5.53B$3.97B
Gross profit$2.18B$2.44B$2.4B$2.21B$1.51B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$780.1M$728.4M$776.4M$778.8M$585.3M
Other expenses$383M$610.2M$667.7M$640.4M$544.4M
Operating expenses$1.16B$1.34B$1.44B$1.42B$1.13B
Cost and expenses$7.24B$7.18B$7.16B$6.95B$5.1B
Interest income$7.11M$8.61M$5.01M$2.35M$570K
Interest expense$188.1M$237.2M$336.7M$229.7M$182.4M
Depreciation and amortization$383M$488.5M$586M$614.7M$360.3M
Ebitda$823.6M$1.56B$1.52B$1.41B$739.4M
Operating income$1.01B$1.1B$956.2M$795.2M$378.5M
Total other income/expenses, net-$-759.99M-$-228.63M-$-331.69M-$-230.52M-$-184.01M
Income before tax$252.5M$869.2M$624.1M$564.7M$194.5M
Income tax expense$23.1M$77.7M$11.8M$59.4M$41.3M
Net income$229.3M$791.5M$612.3M$505.3M$153.2M
Weighted average shares outstanding$78.4M$82.5M$82.1M$81.5M$67.1M
Weighted average diluted shares outstanding$79M$83M$82.7M$82.5M$68.1M
Balance sheet
20252024202320222021
Cash and short-term investments$647.3M$538.8M$380.1M$290.5M$753.9M
Net receivables$2.75B$2.85B$2.9B$2.8B$2.07B
Inventory$0.00$0.00$0.00$7.06M$0.00
Total current assets$3.5B$3.53B$3.41B$3.23B$2.94B
Property, plant and equipment, net$524.7M$530.5M$501.5M$504.2M$534.6M
Goodwill and intangible assets$12B$12.6B$12.9B$13.3B$13.7B
Long-term investments$82.1M$58M$46.8M$32.6M$25M
Total non-current assets$12.8B$13.3B$13.6B$14B$14.4B
Total assets$16.3B$16.9B$17B$17.2B$17.4B
Accounts payable$780.9M$704.6M$595.5M$611.4M$227M
Short-term debt$566M$66.6M$146.6M$98.8M$105.1M
Deferred revenue$1.55B$1.61B$1.65B$1.51B$1.32B
Total current liabilities$3.2B$2.8B$2.83B$2.69B$2.48B
Long-term debt$2.99B$3.54B$3.79B$4.73B$5.54B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$730K
Total non-current liabilities$3.88B$4.56B$4.92B$6B$6.84B
Capital lease obligations$153.4M$176.9M$162.7M$175.3M$209.4M
Total liabilities$7.08B$7.35B$7.75B$8.69B$9.32B
Common stock$6.3M$6.59M$6.7M$6.65M$6.64M
Retained earnings$2.12B$2.72B$2.43B$1.82B$1.42B
Accumulated other comprehensive income (loss)-$-68.53M-$-228.62M-$-142.34M-$-171.54M-$-90.94M
Total equity$9.19B$9.52B$9.24B$8.5B$8.07B
Total investments$82.1M$58M$48.8M$34.3M$26.7M
Total debt$3.56B$3.6B$3.94B$4.83B$5.65B
Net debt$2.91B$3.06B$3.56B$4.54B$4.89B
Cash flow statement
20252024202320222021
Net income$229.3M$791.5M$612.3M$505.3M$153.2M
Depreciation and amortization$383M$528.3M$586M$569.5M$315M
Stock-based compensation$102M$45.9M$55.7M$70.5M$133.8M
Change in working capital-$-98.1M-$-56.51M-$-114.82M-$-550.22M$135M
Accounts receivable-$-169.32M$9.39M-$-78.58M-$-753.29M$95.9M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$1.04B$1.29B$1.16B$563.3M$829.1M
Investments in property, plant and equipment-$-174.21M-$-168.06M-$-140.69M-$-142.16M-$-93.75M
Acquisitions, net-$-2.54M-$-84.16M-$-71.77M-$-1.91M-$-5.92B
Net cash used for investing activities-$-187.53M-$-266.79M-$-226.65M-$-145.87M-$-6.02B
Common stock issued$9.72M$36.2M$51M$35.8M$117.7M
Common stock repurchased-$-750M-$-500M$0.00-$-99.98M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-771.26M-$-837.18M-$-844.04M-$-864.17M$5.11B
Net change in cash$108.5M$160.7M$89.3M-$-463.44M-$-88.09M
Cash at end of period$647.3M$538.8M$378.1M$288.8M$752.2M
Operating cash flow$1.04B$1.29B$1.16B$563.3M$829.1M
Capital expenditure-$-174.21M-$-168.06M-$-140.69M-$-142.16M-$-93.75M
Free cash flow$862M$1.12B$1.02B$421.2M$735.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ICON Public Limited Company

        ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

        CEO
        Barry Balfe
        Employees
        40.35K
        Beta
        1.22

        Explore

        Frequently asked questions

        What is the intrinsic value of ICON Public Limited Company (ICLR)?

        ICON Public Limited Company (ICLR) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ICLR undervalued?

        ICLR trades at a price of $186.71 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.